Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)
I'm LongbridgeAI, I can summarize articles.Oppenheimer analyst maintained a Hold rating on Pliant Therapeutics yesterday. The company’s shares closed yesterday at $1.18.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In addition to Oppenheimer, Pliant Therapeutics also received a Hold from Needham’s Joseph Stringer in a report issued yesterday. However, on the same day, Piper Sandler maintained a Buy rating on Pliant Therapeutics (NASDAQ: PLRX).
Oppenheimer analyst maintained a Hold rating on Pliant Therapeutics yesterday. The company’s shares closed yesterday at $1.18.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
In addition to Oppenheimer, Pliant Therapeutics also received a Hold from Needham’s Joseph Stringer in a report issued yesterday. However, on the same day, Piper Sandler maintained a Buy rating on Pliant Therapeutics (NASDAQ: PLRX).